Vendor Intelligence Report: Anlv Biotechnology

Published 3 Jul 2026. 25-page investigative report on who is behind Anlv Biotechnology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Anlv's lab record is materially better than its paper trail. Across 19 Finnrick lab tests on 5 products, Anlv Biotechnology records 17 passes and 2 failures — an 89% overall pass rate. The spread is not flat: GHK-Cu is the cleanest sampled product, Tirzepatide looks usable only with dose verification, and Tesamorelin is the outlier buyers should avoid unless a fresh batch-matched test resolves it. Stricter fill/purity grading makes the record less forgiving.

The investigation ties the Anlv sales channel to anlvv.com, a Hebei Anlv Biotechnology entity lead, and a named sales representative whose Facebook employment history predates the domain registration. That authenticates a real export-sales footprint, but not legal accountability: no Chinese registry extract, USCC number, manufacturing address, director list, or ownership chain was recovered.

Two non-lab issues drive the buyer risk. Retained PeptideMeter catalog evidence links the Anlv profile to P-2-P/BMK and 4-AP, while the current vendor listing could not be rechecked because the source failed to load. Field records also indicate most tested vials lacked printed batch IDs, weakening the link between a COA, a shipment, and the vial in hand.

Infrastructure does not support the louder sister-brand theory. Anlv shares Alibaba Cloud hosting with an active nutraceutical site and an offline chemical-domain lead, but the report treats that as hosting-level evidence, not ownership proof. Public influencer, coupon, X, and web-indexed Reddit searches found little direct-to-consumer chatter.

Inside the full report:

  • Domain and WHOIS timeline for anlvv.com, including the 2026 nameserver update and Wayback instability
  • Corporate identity file covering the Hebei Anlv lead, Linda Shi Facebook capture, and archived WhatsApp/email contact panel
  • Alibaba Cloud co-hosting analysis of Aidubio and How Chemical, with attribution boundaries
  • Retained PeptideMeter precursor-listing exhibit and the current-status verification dead end
  • Product-specific Finnrick charts, methodology-divergence analysis, and Appendix A laboratory data for all 5 products
  • Lot-traceability and COA-verification checklist for matching vial, invoice, COA, and shipment paperwork

Risk assessment

  • Controlled-precursor catalog risk — high: Retained PeptideMeter capture links Anlv to P-2-P/BMK and 4-AP; current listing could not be rechecked because PeptideMeter vendors page failed.
  • Tesamorelin quality-failure risk — high: Finnrick rates Tesamorelin at 51.73%; retained certificate evidence shows a 10 mg label testing at 3.86 mg with 93.96% purity.
  • Lot traceability and COA-verification risk — high: Field records indicate most tested vials lacked batch IDs, undermining lot-matched COAs, recalls, and buyer verification.
  • Tirzepatide dosing-variance risk — medium: Tirzepatide rates 81.37% across Finnrick's sampled record, but retained detailed testing showed a 20 mg sample at 25.7 mg.
  • Corporate-identity and channel-verification risk — medium: Hebei Anlv is the strongest entity lead, but Chinese registry verification/USCC, official-channel list, and durable current website records were not obtained.